Prospective study on cervical neoplasia IV. Presence of HPV antibodies
Language English Country United States Media print
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
9935175
DOI
10.1002/(sici)1097-0215(19990129)80:3<365::aid-ijc5>3.0.co;2-c
PII: 10.1002/(SICI)1097-0215(19990129)80:3<365::AID-IJC5>3.0.CO;2-C
Knihovny.cz E-resources
- MeSH
- Biomarkers blood MeSH
- DNA-Binding Proteins * MeSH
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Uterine Cervical Neoplasms immunology virology MeSH
- Oncogene Proteins, Viral blood MeSH
- Papillomaviridae immunology MeSH
- Papillomavirus E7 Proteins MeSH
- Prospective Studies MeSH
- Antibodies, Viral blood MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Biomarkers MeSH
- DNA-Binding Proteins * MeSH
- E2 protein, Human papillomavirus type 16 MeSH Browser
- oncogene protein E4, Human papillomavirus type 16 MeSH Browser
- oncogene protein E7, Human papillomavirus type 16 MeSH Browser
- Oncogene Proteins, Viral MeSH
- Papillomavirus E7 Proteins MeSH
- Antibodies, Viral MeSH
Sera collected in the course of a prospective study carried out in Prague in 1975-1983 were assayed for the presence of human papillomavirus (HPV) antibodies. Women with cervical neoplasia proven by biopsy at enrollment possessed antibodies to peptides derived from E2, E4 and E7 proteins of HPV16 and to virus-like particles (VLPs) of HPV16, -18 and -33 significantly more frequently than matched controls. Women without cervical neoplasia at enrollment who developed the disease in the course of the study differed from matched controls by a higher prevalence of antibodies against VLPs of HPV16 and -18 but not against early antigens of HPV16. In 19 of the latter subjects, paired serum specimens were tested, the first samples having been taken at enrollment and the second at diagnosis. Development of the disease was associated with seroconversion from negativity to positivity to at least one HPV antigen in 11 (57.9%) women.
References provided by Crossref.org
